Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that, effective on August 1, 2020, the Compensation Committee of Blueprint Medicines' Bo
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of -9.62% and 10.36%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 07/30 12:35
The Daily Biotech Pulse: Bristol-Myers, Bluebird Bio Resubmit Multiple Myeloma Drug BLA, FSD To Close Medicinal Cannabis Business, Hologic's Blowout Quarter
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29)
Blueprint Medicines (NASDAQ:BPMC) reported quarterly losses of $(2.28) per share which missed the analyst consensus estimate of $(2.14) by 6.54 percent. This is a 11.76 percent decrease over losses of $(2.04) per share
Benzinga · 07/30 11:45
Blueprint Medicines Reports Second Quarter 2020 Financial Results
Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today reported financial results and provided a business update for the second quarter ended June 30, 202
PR Newswire · 07/30 11:00
Blueprint Medicines Corporation (BPMC) CEO Jeff Albers on Q2 2020 Results - Earnings Call Transcript